B
Workshop Task and Agenda
WORKSHOP TASK
A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize and conduct a public workshop that brings together experts and key stakeholders from academia, government, industry, and nonprofit organizations to explore biomarkers for uses such as diagnosis, monitoring, and treatment evaluation of traumatic brain injury (TBI). Presentations and discussions may be designed to
- Review the landscape of TBI biomarkers, including blood-based, imaging-based, and other types of relevant physiological markers;
- Explore clinical needs, challenges, and potential opportunities to advance implementation of Food and Drug Administration (FDA)-approved biomarkers for TBI; and
- Discuss open research questions, evidence needs, and potential opportunities to inform further biomarker design and validation for TBI.
A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
WORKSHOP AGENDA
(All times ET)
| 9:15–9:30 am |
WELCOME: INTRODUCTION AND GOALS OF THE WORKSHOP
Corinne Peek-Asa, University of California, San Diego; Acting Chair, Forum on Traumatic Brain Injury Stuart Hoffman, Department of Veterans Affairs, Workshop Planning Committee |
| 9:30–10:40 am |
SESSION 1: ORIENTATION TO TBI BIOMARKERS AND CLINICAL NEEDS
Moderator: Geoffrey Manley, University of California, San Francisco
How Can Biomarkers for TBI Inform Clinical Care and Research? Ramon Diaz-Arrastia, University of Pennsylvania Perspectives from the TBI Community on the Role of Biomarkers in Addressing Unmet Needs Rachel Lazarus, AARP Jeffrey Bazarian, University of Rochester Lessons from Validation and Use of Biomarkers to Inform Cardiology Care and Research Alan Wu, San Francisco General Hospital Discussion |
| 10:40–11:00 am | Break |
| 11:00–12:40 pm |
SESSION 2: MAJOR CLASSES OF TBI BIOMARKERS
Moderator: Luca Marinelli, GE Research Syntheses of several classes of TBI biomarkers, including where on the continuum of care such biomarkers have demonstrated utility, barriers to their implementation in clinical practice, and open research gaps and questions Neuroimaging Biomarkers Elisabeth Wilde, University of Utah Biomarkers Detectable in Blood Jessica Gill, Johns Hopkins University Electrophysiological Biomarkers Paul Rapp, Uniformed Services University and University of California, Irvine Other Physiological Markers Christina Master, University of Pennsylvania Discussion |
| 12:40–1:30 pm | Lunch |
| 1:30–2:30 pm |
SESSION 3: DEVELOPMENT OF BIOMARKERS IN THE TRANSLATIONAL PIPELINE
Moderator: Stuart Hoffman, Department of Veterans Affairs Pharmacodynamic Response Biomarkers Patrick Kochanek, University of Pittsburgh Combining Multimodal Information to Improve Diagnosis, Prognostication, and Understanding of Longer-Term Outcomes David Okonkwo, University of Pittsburgh Discussion |
| 2:30–2:50 pm | Break |
| 2:50–3:50 pm |
SESSION 4: NEEDS AND OPPORTUNITIES TO ADVANCE THE USE OF BIOMARKERS FOR TBI CARE AND RESEARCH
Moderator: Frederick Korley, University of Michigan
Panelists: Martin Schreiber, Oregon Health and Science University Beth McQuiston, Abbott Laboratories Allison Kumar, Arina Consulting Carol Taylor-Burds, National Institute of Neurological Disorders and Stroke (NINDS) Narayan Iyer, Biomedical Advanced Research and Development Authority (BARDA) CAPT Travis Polk, DoD Combat Casualty Care Research Program |
| 3:50–4:45 pm |
SESSION 5: LOOKING AHEAD: WORKSHOP THEMES AND KEY MESSAGES
Moderator: Leslie Prichep, BrainScope Company
|
| 4:45 pm |
WRAP-UP REMARKS
Corinne Peek-Asa, Acting Chair, Forum on Traumatic Brain Injury |
| 4:50 pm |
ADJOURN
Forum reception to follow |
